Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin
- Sponsor
- Handok Inc.
- Study ID
- NCT04431141
- Phase
- PHASE1
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 19 Years - 45 Years
- Healthy Volunteers
- Accepted
Interventions
- Teneligliptin — DRUGTeneligliptin alone
- Empagliflozin — DRUGEmpagliflozin alone
- Teneligliptin and Empagliflozin — DRUGTeneligliptin and empagliflozin
Study Details
This study is to evaluate pharmacokinetic drug interaction between teneligliptin and empagliflozin in healthy adults.
Key Dates
- Start date
- Sep 15, 2020
- Status verified
- Nov 2021
- Primary completion
- Nov 16, 2020
- Completion
- Jan 25, 2021
Study Design
- Enrollment
- 32 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: Teneligliptin
- Experimental: Empagliflozin
- Experimental: Teneligliptin and Empagliflozin
Primary Outcome Measure
Cmax,ss of teneligliptin and empagliflozin [ Time Frame: 72 hours ]
Related Studies
- Uric Acid Lowering Trial in Youth Onset T2DPHASE2 · Recruiting · University of Colorado, Denver · Aurora, Colorado
- Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)Recruiting · Petter Bjornstad · Aurora, Colorado
- Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney DiseasePHASE3 · Recruiting · Prokidney · Huntsville, Alabama
- A Study of Glycemic Control in Left Ventricular AssistRecruiting · Mayo Clinic · Rochester, Minnesota